Hello, Welcome to Shine Consultant !
Summit & Event Shine Speaker Bureau Shine Advisor Shine Event Service
  • Summit & Event :
    With field research of markets and industries which is analyzed from a global strategic perspective by our professional teams, as well as hot topics which interest leadership and management, Shine Consultant provides you with one-stop platform of dialogue, practice -sharing and social network!
  • Shine Speaker Bureau:
    Committed to provide keynote speakers, executive learning masterclasses and boardroom advisory for global enterprises and institutions, each service provides a deeper and more interactive experience, especially for small, selected audiences and key individuals. We have the resources of the most influential business leaders and experts, who are the most outstanding representatives in their fields. Our team consists of experienced speech and event managers, and we focus on building long-term and in-depth partnerships.
  • Shine Advisor:
    As world-class insight network, we connects clients-decision makers with vetted subject matter experts-advisors. Our clients leverage the insights and perspectives shared by our advisors to stay informed and make better business decisions.We have over 600,000 Shine Advisors in 20 industries, which continues to grow every day.
  • Shine Event Service:
    Committed to be the world's most professional provider of industrial Summit & Event. We provide one-stop professional services, including investigating and planning, on-demand inviting, marketing and promoting, operating, project management, live& digital conference, each service is performed by an experienced professional team matched with long-term industrial resources. We focus on establishing long-term and in-depth partnerships.
Guest Information
Xiang S Ye
Xiang S Ye

Lilly Oncology Discovery China/Asia

Dr. Xiang S Ye is executive director of Lilly Oncology Discovery China/Asia. Dr. Ye joined Eli Lilly in early 1998. At Lilly, Dr. Ye led discovery research efforts for novel cancer drugs targeting cancer cell cycle and signaling and delivered 8 clinical candidates, including abemaciclib, a CDK4/6 inhibitor, designated as a breakthrough medicine, and approved by FDA in 2017. In 2008, Dr. Ye served as an Enduring Team Leader and led a group of scientists across the drug R&D value chain in a corporate initiative to speed up drug development and had the responsibility in managing a LO to Phase II portfolio. The team delivered 4 clinical candidates, 2 IND and a Phase II milestones. Dr. Ye has published more than 60 scientific papers and book chapters. Dr. Ye was relocated to Shanghai in 2011 to lead Lilly Oncology Discovery China/Asia and delivered the first clinical candidate in early 2014 from China discovery research. In his current role, Dr. Ye also supervised postdoctoral scientists in China, served as corporate supervisor at Shanghai Science and Technology University, and has leadership roles in several pre-competitive consortia programs, and industry and academic collaborations to promote cancer research and drug development in China/Asia.